Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharmaceuticals
Epic: SPL
News: Latest news
Web Site: Starpharma
Other Articles: 16-08-201016-08-201015-07-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 02, 11:00Baobab Resources identifies distinct ore domain at Tete’s South Zone

Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Thursday September 02, 08:15Indonesia edges closer toward uranium mining and nuclear power

After nearly five decades of national debate on the issue, Indonesia's central government may finally be ready to develop a national nuclear policy, which may lead to domestic uranium mining.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 01:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Starpharma

Starpharma

Starpharma is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications.  The lead pharmaceutical development product is VivaGel®, a vaginal microbicide designed to prevent the transmission of HIV and genital herpes.  Starpharma is developing a VivaGel®-coated condom under a licence agreement with SSL International plc (LSE:SSL), manufacturer of Durex®, the market-leading condom brand worldwide.  Products based on Starpharma’s technology are on the market as diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.  Starpharma is exploring dendrimer opportunities in materials science applications including water remediation and animal health products.

CLICK HERE FOR FULL ANLAYSIS OF STARPHARMA
Wednesday, June 30, 2010

Starpharma and Monash University get grant for new nanotech drug delivery method

company news image

Dendrimer nanotechnology specialist Starpharma (ASX:SPL, OTC:SPHRY) has been awarded a  A$420,000 Australian Research Council (ARC) funding grant, alongside the Monash Institute of Pharmaceutical Sciences (MIPS), to advance a new drug delivery method which may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions.

According to the lead researcher at MIPS, Professor Chris Porter, the technology has particular implications for the treatment of diseases which are spread via the lymphatics and lymph nodes. The delivery method is based on dendrimer technology. Dendrimers are precisely defined bio-friendly molecules which are 3-10 nanometres in diameter.

Australia’s Innovation Minister Kim Carr awarded Starpharma and MIPS A$420,000 as part of the ARC’s Linkage Projects scheme. The scheme is designed to encourage Australian institutions to undertake innovative and cutting-edge research projects in collaboration with industry and other partners.

According to Starpharma, Dendrimers have a surface with has many different sites on which drugs and other functional groups may be attached, allowing the optimisation of how the drug interacts with the body. “Our work so far suggests that careful design of the size and surface characteristics of certain dendrimers provides an opportunity to boost delivery to the lymphatic system, signalling the potential to significantly improve patient treatment,” Professor Porter added. 

“This Linkage grant provides an excellent opportunity to explore these issues in detail and to advance the development of targeted therapeutics.”

“This funding will assist in advancing our collaboration with researchers from Monash University over the next three years, to further understand the full potential of Starpharma’s proprietary dendrimers in improving drug delivery”, Starpharma chief executive Dr Jackie Fairley commented. “This research has the potential to significantly improve the treatment of diseases, including metastatic cancer, lymphoma, HIV and metastitial tuberculosis.”

Starpharma highlighted that with the ability to target therapeutics in this way, there is the potential to enhance efficacy and reduce side effects and toxicity of treatments. Furthermore, the approach also prolongs the lifetime of the drug, by slowing the process of drug breakdown, which maximises the opportunities for the drug to reach the relevant sites in the body before being cleared by the body’s natural mechanisms.

AddThis Feed Button
Register here to be notified of future Starpharma articles.

Other Starpharma articles


Other Starpharma news

More news ►

Investors interested in Starpharma recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.